Overview

The marketing authorisation for Zalviso has been withdrawn at the request of the marketing authorisation holder.

български (BG) (760.64 KB - PDF)

View

español (ES) (667.71 KB - PDF)

View

čeština (CS) (739.15 KB - PDF)

View

dansk (DA) (665.9 KB - PDF)

View

Deutsch (DE) (670.41 KB - PDF)

View

eesti keel (ET) (665.35 KB - PDF)

View

ελληνικά (EL) (762.93 KB - PDF)

View

français (FR) (669.36 KB - PDF)

View

hrvatski (HR) (686.42 KB - PDF)

View

italiano (IT) (666.44 KB - PDF)

View

latviešu valoda (LV) (738.28 KB - PDF)

View

lietuvių kalba (LT) (688.61 KB - PDF)

View

magyar (HU) (733.2 KB - PDF)

View

Malti (MT) (741.01 KB - PDF)

View

Nederlands (NL) (667.09 KB - PDF)

View

polski (PL) (738.41 KB - PDF)

View

português (PT) (668.03 KB - PDF)

View

română (RO) (688.79 KB - PDF)

View

slovenčina (SK) (737.52 KB - PDF)

View

slovenščina (SL) (730.65 KB - PDF)

View

Suomi (FI) (665.44 KB - PDF)

View

svenska (SV) (667.37 KB - PDF)

View

Product information

български (BG) (2.02 MB - PDF)

View

español (ES) (1.14 MB - PDF)

View

čeština (CS) (1.73 MB - PDF)

View

dansk (DA) (1.14 MB - PDF)

View

Deutsch (DE) (1.08 MB - PDF)

View

eesti keel (ET) (1.15 MB - PDF)

View

ελληνικά (EL) (2.07 MB - PDF)

View

français (FR) (1.17 MB - PDF)

View

hrvatski (HR) (1.23 MB - PDF)

View

íslenska (IS) (1.11 MB - PDF)

View

italiano (IT) (1.08 MB - PDF)

View

latviešu valoda (LV) (3.17 MB - PDF)

View

lietuvių kalba (LT) (1.21 MB - PDF)

View

magyar (HU) (1.8 MB - PDF)

View

Malti (MT) (1.81 MB - PDF)

View

Nederlands (NL) (1.13 MB - PDF)

View

norsk (NO) (1.14 MB - PDF)

View

polski (PL) (1.77 MB - PDF)

View

português (PT) (1.14 MB - PDF)

View

română (RO) (1.24 MB - PDF)

View

slovenčina (SK) (1.72 MB - PDF)

View

slovenščina (SL) (1.74 MB - PDF)

View

Suomi (FI) (1.05 MB - PDF)

View

svenska (SV) (1.14 MB - PDF)

View

Latest procedure affecting product information: T/0017

05/08/2022

Globe icon

This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

български (BG) (630.83 KB - PDF)

View

español (ES) (589.36 KB - PDF)

View

čeština (CS) (612.66 KB - PDF)

View

dansk (DA) (588.95 KB - PDF)

View

Deutsch (DE) (588.89 KB - PDF)

View

eesti keel (ET) (588.92 KB - PDF)

View

ελληνικά (EL) (629.13 KB - PDF)

View

français (FR) (589.08 KB - PDF)

View

hrvatski (HR) (600.21 KB - PDF)

View

íslenska (IS) (588.96 KB - PDF)

View

italiano (IT) (589.31 KB - PDF)

View

latviešu valoda (LV) (622.41 KB - PDF)

View

lietuvių kalba (LT) (605.38 KB - PDF)

View

magyar (HU) (618.12 KB - PDF)

View

Malti (MT) (620.25 KB - PDF)

View

Nederlands (NL) (589.22 KB - PDF)

View

norsk (NO) (589.15 KB - PDF)

View

polski (PL) (620.57 KB - PDF)

View

português (PT) (589.37 KB - PDF)

View

română (RO) (606.42 KB - PDF)

View

slovenčina (SK) (619.68 KB - PDF)

View

slovenščina (SL) (618.15 KB - PDF)

View

Suomi (FI) (589.19 KB - PDF)

View

svenska (SV) (589.02 KB - PDF)

View

Product details

Name of medicine
Zalviso
Active substance
sufentanil
International non-proprietary name (INN) or common name
sufentanil
Therapeutic area (MeSH)
Pain, Postoperative
Anatomical therapeutic chemical (ATC) code
N01AH03

Pharmacotherapeutic group

Anesthetics

Therapeutic indication

Zalviso is indicated for the management of acute moderate to severe post-operative pain in adult patients.

Authorisation details

EMA product number
EMEA/H/C/002784
Marketing authorisation holder
FGK Representative Service GmbH

Heimeranstrasse 35
80338 Munich
Germany

Opinion adopted
23/07/2015
Marketing authorisation issued
18/09/2015
Revision
7

Assessment history

Topics

This page was last updated on

How useful do you find this page?